Arterioscler Thromb Vasc Biol

Slides:



Advertisements
Similar presentations
Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)
Advertisements

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Trends in Vascular Complications After Diagnostic.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. Patterns and Predictors of Stress Testing Modality After.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Fibrinogen Rather Than Residual.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Drug-Eluting Versus Bare-Metal Stents During PCI.
Hypercholesterolemia Enhances Thromboembolism in Arterioles but Not Venules by Martijn A.W. Broeders, Geert Jan Tangelder, Dick W. Slaaf, Robert S. Reneman,
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
Driving Times and Distances to Hospitals With Percutaneous Coronary Intervention in the United States by Brahmajee K. Nallamothu, Eric R. Bates, Yongfei.
Circ Cardiovasc Interv
Calcification burden of the femoropopliteal artery demonstrating progression from a healthy artery with no calcification (0) to advanced calcific deposits.
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.
Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
by Alexander Kulik, Ian G. Burwash, Varun Kapila, Thierry G
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
New LINE(s) of Evidence for Genetic Regulation of Platelets
Arterioscler Thromb Vasc Biol
Sex-Related Differences in Fractional Flow Reserve–Guided Treatment
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.
Assessment of Unstable Atherosclerosis in Mice
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Contribution of Stroke to the Cochrane Stroke Group Trials Register
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Infusion of CSL112 increases total cholesterol efflux capacity (CEC) regardless of baseline functional apolipoprotein A-I (apoA-I) activity. Infusion of.
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Pulse Pressure and Resistance Artery Structure in the Elderly
by Karen Reue, Robert D. Cohen, and Michael C. Schotz
Circ Cardiovasc Interv
Arterioscler Thromb Vasc Biol
Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis  Islam Y. Elgendy,
William Insull, MD  The American Journal of Medicine 
Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies  Hisato Takagi,
Tornado diagram of one-way deterministic sensitivity analysis.
John A. Bittl et al. JACC 2016;68:
Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD 
Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock 
(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,
Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.
Forest plot illustrating risk ratio of stent thrombosis
Presentation transcript:

Arterioscler Thromb Vasc Biol Altered Plasma Fibrin Clot Properties Are Associated With In-Stent Thrombosis by Anetta Undas, Jaroslaw Zalewski, Marek Krochin, Zbigniew Siudak, Marcin Sadowski, Jerzy Pregowski, Dariusz Dudek, Marianna Janion, Adam Witkowski, and Krzysztof Zmudka Arterioscler Thromb Vasc Biol Volume 30(2):276-282 February 1, 2010 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Study flow chart. Figure 1. Study flow chart. IST indicates in-stent thrombosis; PCI, percutaneous coronary intervention. Anetta Undas et al. Arterioscler Thromb Vasc Biol. 2010;30:276-282 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Multiple logistic regression analysis with in-stent thrombosis as a dependent variable. Figure 2. Multiple logistic regression analysis with in-stent thrombosis as a dependent variable. Ks indicates clot permeability; ΔAbsmax (405 nm), maximum absorbance of fibrin gel at 405 nm determined by using turbidimetry; D-Drate, maximum rate of d-dimer release from clots; RLDB, reference lumen diameter before first stenting; OR, odds ratio; CI, confidence intervals. Anetta Undas et al. Arterioscler Thromb Vasc Biol. 2010;30:276-282 Copyright © American Heart Association, Inc. All rights reserved.